Castle Creek discontinues Phase II of epidermolysis bullosa compound

Castle Creek Pharmaceuticals LLC (Parsippany, N.J.) discontinued the Phase II DELIVERS trial evaluating topical 1% diacerein (AC-203, CCP-020) to treat epidermolysis bullosa simplex (EBS). According to ClinicalTrials.gov, an IDMC said the trial will not meet its statistical objectives.

The double-blind, placebo-controlled, international trial enrolled 80 patients. The primary endpoint was the proportion of patients who achieve a ≥40% reduction in body surface area (BSA) of EBS lesions...